Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

By G. Kenter, M. Welters, A. Valentijn, M. Lowik, Dorien M. A. Berends-van der Meer, A. Vloon, Farah Essahsah, Lorraine M. Fathers, R. Offringa, J. Drijfhout and 5 more. New England Journal of Medicine, 2009

1,066 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Surgery

View Paper: https://www.semanticscholar.org/paper/cfd66626bde0cdc5391cbde45124dc7e203b2288

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. L. Zitvogel
2. Guido Kroemer
3. Oliver Kepp
4. Jacques Banchereau
5. L. Galluzzi
6. Beth Levine
7. Douglas R. Green
8. Alec C. Kimmelman

In Immunology

1. Guido Kroemer
2. L. Zitvogel
3. Jacques Banchereau
4. Oliver Kepp
5. S. Rosenberg
6. K. Palucka
7. N. Restifo
8. M. Dudley

In Surgery

1. Guido Kroemer

Citations in the corpus

• Immune parameters affecting the efficacy of chemotherapeutic regimens (2011, background): “In 2009, a promising trial demonstrated the therapeutic efficacy of large peptide antigens to eradicate vulvar intraepithelial neoplasias that are positive for human papilloma virus”
• Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “…of 20 individuals with high-grade vulvar intraepithelial neoplasia with a long peptide covering the two oncogenic proteins E6 and E7 of high-risk human papilloma virus type 16 (HPV16) led to complete regression of all lesions and eradication of virus in nine individuals (Kenter et al., 2009).”
• Adoptive immunotherapy for cancer: harnessing the T cell response (2012, background): “Belirli bir kanser histolojisinin alt tipine uygulanabilir olmasına rağmen, EBV ve HPV gibi kanser ilişkili virüslerden üretilmiş onkojenik proteinleri hedeflemek mümkündür (28,29).”
• Therapeutic cancer vaccines. (2010, background): “Tsuji T, et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.”
• Cancer immunotherapy comes of age (2011, positive): “A recent study of peptides derived from the HPV-16 E6 and E7 viral oncoproteins administered in incomplete Freund’s adjuvant showed clinical responses in 15 of 19 women with vulvar intraepithelial neoplasi”
• Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. (2012, background): “In tumour types that have a well-documented viral origin, such as cervical cancer, caused by the human papillomavirus [5], or hepatocellular carcinoma caused by the hepatitis B virus [6], viral proteins can also serve as tumour antigens and targets for antitumour immune response [7].”